Meeting
2023 ASCO Breakthrough
The impact of low muscle mass and strength on chemotherapy toxicity in women with early breast cancer.
Authors
Andree Kurniawan Jr.
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
Andree Kurniawan Jr., Ratna Djuwita Hatma Sr., Asri Adisasmita Sr., Sonar Soni Panigoro , Noorwati Sutandyo Sr., Fiastuti Witjaksono , Tirza Z Tamin , Rachmat Sumantri , Dwi Savitri Rivami
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Multimodality Treatments
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 9)
DOI
10.1200/GO.2023.9.Supplement_1.9
Abstract #
9
Poster Bd #
B3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CT scan versus bioelectrical impedance spectrometry sarcopenia assessment to predict chemotherapy toxicity in early breast cancer.
First Author: Gabriel Aleixo
Poster
2017 ASCO Annual Meeting
Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC).
First Author: Jenny Furlanetto
Poster
2015 ASCO Annual Meeting
Impact of BMI on survival and toxicity in early breast cancer: An exploratory analysis of prospective randomized phase III study N-SAS BC02 and 03.
First Author: Yoichi Naito
Poster
2014 ASCO Annual Meeting
Estrogen levels in premenopausal (prem) patients (pts) with hormone-receptor positive (HR+) early breast cancer (BC) receiving adjuvant triptorelin (Trip) plus exemestane (E) or tamoxifen (T) in the SOFT trial: SOFT-EST substudy.
First Author: Meritxell Bellet